Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1999 Dec;52(12):876–879. doi: 10.1136/jcp.52.12.876

Prognostic evaluation of metallothionein expression in human colorectal neoplasms.

E E Ioachim 1, A C Goussia 1, N J Agnantis 1, M Machera 1, E V Tsianos 1, A M Kappas 1
PMCID: PMC501652  PMID: 10711249

Abstract

AIM: To investigate the role of metallothionein in colorectal tumours and the possible relation with other factors associated with tumour progression: expression of cathepsin D (CD), CD44, p53, Rb, bcl-2, c-erbB-2, epidermal growth factor receptor (EGFR), proliferation indices (Ki-67, proliferating cell nuclear antigen (PCNA)), and conventional clinicopathological variables. METHODS: The immunohistochemical expression of metallothionein was investigated in 23 cases of colorectal adenoma and 94 adenocarcinomas. Metallothionein expression was examined by the avidinbiotin peroxidase immunoperoxidase (ABC) using the monoclonal mouse antibody E9, on formalin fixed, paraffin embedded tissue. RESULTS: Positive metallothionein expression (> 5% of neoplastic cells) was observed in 30.4% of adenomas and 25.5% of adenocarcinomas, while 8.7% of adenomas and 14.9% carcinomas showed focal metallothionein positivity. In contrast, 60.9% of adenomas and 59.6% of carcinomas almost completely lacked metallothionein expression. In the series of adenocarcinomas, metallothionein expression was inversely correlated with CD44 in neoplastic cells (p = 0.01). There was no statistically significant difference of metallothionein expression, or the other variables examined, between adenocarcinomas and adenomas. CONCLUSIONS: Metallothionein expression does not seem to indicate aggressive biological behaviour in colorectal adenocarcinomas, in comparison with the other types of carcinoma. The inverse correlation with CD44 could suggest that the decreased metallothionein expression may contribute to the metastatic spread of the lymph node involvement in colorectal cancer. Metallothionein expression does not seem to represent an independent prognostic marker in colorectal cancer.

Full text

PDF
876

Images in this article

877Image
on p.877

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrews P. A., Murphy M. P., Howell S. B. Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol. 1987;19(2):149–154. doi: 10.1007/BF00254568. [DOI] [PubMed] [Google Scholar]
  2. Banerjee D., Onosaka S., Cherian M. G. Immunohistochemical localization of metallothionein in cell nucleus and cytoplasm of rat liver and kidney. Toxicology. 1982;24(2):95–105. doi: 10.1016/0300-483x(82)90048-8. [DOI] [PubMed] [Google Scholar]
  3. Bier B., Douglas-Jones A., Tötsch M., Dockhorn-Dworniczak B., Böcker W., Jasani B., Schmid K. W. Immunohistochemical demonstration of metallothionein in normal human breast tissue and benign and malignant breast lesions. Breast Cancer Res Treat. 1994;30(3):213–221. doi: 10.1007/BF00665963. [DOI] [PubMed] [Google Scholar]
  4. Cherian M. G., Huang P. C., Klaassen C. D., Liu Y. P., Longfellow D. G., Waalkes M. P. National Cancer Institute workshop on the possible roles of metallothionein in carcinogenesis. Cancer Res. 1993 Feb 15;53(4):922–925. [PubMed] [Google Scholar]
  5. De Potter C. R., Beghin C., Makar A. P., Vandekerckhove D., Roels H. J. The neu-oncogene protein as a predictive factor for haematogenous metastases in breast cancer patients. Int J Cancer. 1990 Jan 15;45(1):55–58. doi: 10.1002/ijc.2910450112. [DOI] [PubMed] [Google Scholar]
  6. Douglas-Jones A. G., Schmid K. W., Bier B., Horgan K., Lyons K., Dallimore N. D., Moneypenny I. J., Jasani B. Metallothionein expression in duct carcinoma in situ of the breast. Hum Pathol. 1995 Feb;26(2):217–222. doi: 10.1016/0046-8177(95)90040-3. [DOI] [PubMed] [Google Scholar]
  7. Fresno M., Wu W., Rodriguez J. M., Nadji M. Localization of metallothionein in breast carcinomas. An immunohistochemical study. Virchows Arch A Pathol Anat Histopathol. 1993;423(3):215–219. doi: 10.1007/BF01614773. [DOI] [PubMed] [Google Scholar]
  8. Haerslev T., Jacobsen K., Nedergaard L., Zedeler K. Immunohistochemical detection of metallothionein in primary breast carcinomas and their axillary lymph node metastases. Pathol Res Pract. 1994 Aug;190(7):675–681. doi: 10.1016/S0344-0338(11)80746-6. [DOI] [PubMed] [Google Scholar]
  9. Hainaut P., Milner J. A structural role for metal ions in the "wild-type" conformation of the tumor suppressor protein p53. Cancer Res. 1993 Apr 15;53(8):1739–1742. [PubMed] [Google Scholar]
  10. Hamer D. H. Metallothionein. Annu Rev Biochem. 1986;55:913–951. doi: 10.1146/annurev.bi.55.070186.004405. [DOI] [PubMed] [Google Scholar]
  11. Hsu S. M., Raine L., Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981 Apr;29(4):577–580. doi: 10.1177/29.4.6166661. [DOI] [PubMed] [Google Scholar]
  12. Ioachim E., Goussia A., Agnantis N. J. Glycoprotein CD44 expression in colorectal neoplasms. An immuno-histochemical study including correlation with cathepsin D, extracellular matrix components, p53, Rb, bcl-2, c-erbB-2, EGFR and proliferation indices. Virchows Arch. 1999 Jan;434(1):45–50. doi: 10.1007/s004280050303. [DOI] [PubMed] [Google Scholar]
  13. Jackson P. A., Green M. A., Pouli A., Hubbard R., Marks C. G., Cook M. G. Relation between stage, grade, proliferation, and expression of p53 and CD44 in adenomas and carcinomas of the colorectum. J Clin Pathol. 1995 Dec;48(12):1098–1101. doi: 10.1136/jcp.48.12.1098. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Jasani B., Campbell F., Navabi H., Schmid K. W., Williams G. T. Clonal overexpression of metallothionein is induced by somatic mutation in morphologically normal colonic mucosa. J Pathol. 1998 Feb;184(2):144–147. doi: 10.1002/(SICI)1096-9896(199802)184:2<144::AID-PATH998>3.0.CO;2-J. [DOI] [PubMed] [Google Scholar]
  15. Kelley S. L., Basu A., Teicher B. A., Hacker M. P., Hamer D. H., Lazo J. S. Overexpression of metallothionein confers resistance to anticancer drugs. Science. 1988 Sep 30;241(4874):1813–1815. doi: 10.1126/science.3175622. [DOI] [PubMed] [Google Scholar]
  16. Leber A. P., Miya T. S. A mechanism for cadmium- and zinc-induced tolerance to cadmium toxicity: involvement of metallothionein. Toxicol Appl Pharmacol. 1976 Sep;37(3):403–414. doi: 10.1016/0041-008x(76)90202-7. [DOI] [PubMed] [Google Scholar]
  17. Mulder T. P., Verspaget H. W., Janssens A. R., de Bruin P. A., Griffioen G., Lamers C. B. Neoplasia-related changes of two copper (Cu)/zinc (Zn) proteins in the human colon. Free Radic Biol Med. 1990;9(6):501–506. doi: 10.1016/0891-5849(90)90128-6. [DOI] [PubMed] [Google Scholar]
  18. Nath R., Kambadur R., Gulati S., Paliwal V. K., Sharma M. Molecular aspects, physiological function, and clinical significance of metallothioneins. Crit Rev Food Sci Nutr. 1988;27(1):41–85. doi: 10.1080/10408398809527477. [DOI] [PubMed] [Google Scholar]
  19. Ofner D., Maier H., Riedmann B., Bammer T., Rumer A., Winde G., Böcker W., Jasani B., Schmid K. W. Immunohistochemical metallothionein expression in colorectal adenocarcinoma: correlation with tumour stage and patient survival. Virchows Arch. 1994;425(5):491–497. doi: 10.1007/BF00197552. [DOI] [PubMed] [Google Scholar]
  20. Ohshio G., Imamura T., Okada N., Wang Z. H., Yamaki K., Kyogoku T., Suwa H., Yamabe H., Imamura M. Immunohistochemical study of metallothionein in pancreatic carcinomas. J Cancer Res Clin Oncol. 1996;122(6):351–355. doi: 10.1007/BF01220802. [DOI] [PubMed] [Google Scholar]
  21. Riordan J. R., Richards V. Human fetal liver contains both zinc- and copper-rich forms of metallothionein. J Biol Chem. 1980 Jun 10;255(11):5380–5383. [PubMed] [Google Scholar]
  22. Rydén L., Deutsch H. F. Preparation and properties of the major copper-binding component in human fetal liver. Its identification as metallothionein. J Biol Chem. 1978 Jan 25;253(2):519–524. [PubMed] [Google Scholar]
  23. Schmid K. W., Ellis I. O., Gee J. M., Darke B. M., Lees W. E., Kay J., Cryer A., Stark J. M., Hittmair A., Ofner D. Presence and possible significance of immunocytochemically demonstrable metallothionein over-expression in primary invasive ductal carcinoma of the breast. Virchows Arch A Pathol Anat Histopathol. 1993;422(2):153–159. doi: 10.1007/BF01607167. [DOI] [PubMed] [Google Scholar]
  24. Slater E. P., Cato A. C., Karin M., Baxter J. D., Beato M. Progesterone induction of metallothionein-IIA gene expression. Mol Endocrinol. 1988 Jun;2(6):485–491. doi: 10.1210/mend-2-6-485. [DOI] [PubMed] [Google Scholar]
  25. Tanabe K. K., Ellis L. M., Saya H. Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. Lancet. 1993 Mar 20;341(8847):725–726. doi: 10.1016/0140-6736(93)90490-8. [DOI] [PubMed] [Google Scholar]
  26. Thornalley P. J., Vasák M. Possible role for metallothionein in protection against radiation-induced oxidative stress. Kinetics and mechanism of its reaction with superoxide and hydroxyl radicals. Biochim Biophys Acta. 1985 Jan 21;827(1):36–44. doi: 10.1016/0167-4838(85)90098-6. [DOI] [PubMed] [Google Scholar]
  27. Webb M., Cain K. Functions of metallothionein. Biochem Pharmacol. 1982 Jan 15;31(2):137–142. doi: 10.1016/0006-2952(82)90202-7. [DOI] [PubMed] [Google Scholar]
  28. Webber M. M., Rehman S. M., James G. T. Metallothionein induction and deinduction in human prostatic carcinoma cells: relationship with resistance and sensitivity to adriamycin. Cancer Res. 1988 Aug 15;48(16):4503–4508. [PubMed] [Google Scholar]
  29. Wielenga V. J., Heider K. H., Offerhaus G. J., Adolf G. R., van den Berg F. M., Ponta H., Herrlich P., Pals S. T. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res. 1993 Oct 15;53(20):4754–4756. [PubMed] [Google Scholar]
  30. Zelger B., Hittmair A., Schir M., Ofner C., Ofner D., Fritsch P. O., Böcker W., Jasani B., Schmid K. W. Immunohistochemically demonstrated metallothionein expression in malignant melanoma. Histopathology. 1993 Sep;23(3):257–263. doi: 10.1111/j.1365-2559.1993.tb01198.x. [DOI] [PubMed] [Google Scholar]
  31. Zeng J., Heuchel R., Schaffner W., Kägi J. H. Thionein (apometallothionein) can modulate DNA binding and transcription activation by zinc finger containing factor Sp1. FEBS Lett. 1991 Feb 25;279(2):310–312. doi: 10.1016/0014-5793(91)80175-3. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES